CytomX Therapeutics (CTMX) Depreciation & Amortization (CF) (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Depreciation & Amortization (CF) came in at $214000.0 in Q1 2026, down 38.68% YoY from $349000.0 in Q1 2025, and down 54.76% on a QoQ basis from $473000.0 in Q4 2025.
CytomX Therapeutics (CTMX) Depreciation & Amortization (CF) (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Depreciation & Amortization (CF) data on file, last reported at $214000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 38.68% year-over-year to $214000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 28.9% YoY) and the FY2025 annual result came in at $1.2 million, down 24.17% from the prior year.
- Depreciation & Amortization (CF) slipped to $214000.0 in Q1 2026, from $473000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $586000.0 in Q3 2022 to a low of $98000.0 in Q3 2025.
- A 5-year average of $434823.5 and a median of $448000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The widest YoY moves for Depreciation & Amortization (CF): up 25.8% in 2025, down 75.06% in 2025.
- Tracing CTMX's Depreciation & Amortization (CF) over 5 years: stood at $572000.0 in 2022, then dropped by 21.5% to $449000.0 in 2023, then dropped by 16.26% to $376000.0 in 2024, then grew by 25.8% to $473000.0 in 2025, then plunged by 54.76% to $214000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $214000.0 (Q1 2026), $473000.0 (Q4 2025), and $98000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 11,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11,000.00 |
| Jun 30, 2026 | 11,000.00 |
| Mar 31, 2026 | 214,000.00 |
| Mar 31, 2026 | 214,000.00 |
| Dec 31, 2025 | 473,000.00 |
| Dec 31, 2025 | 473,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Jun 30, 2025 | 310,000.00 |
| Jun 30, 2025 | 310,000.00 |
| Mar 31, 2025 | 349,000.00 |
| Mar 31, 2025 | 349,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Sep 30, 2024 | 393,000.00 |
| Sep 30, 2024 | 393,000.00 |
| Jun 30, 2024 | 422,000.00 |
| Jun 30, 2024 | 422,000.00 |
| Mar 31, 2024 | 431,000.00 |
| Mar 31, 2024 | 431,000.00 |